392 related articles for article (PubMed ID: 33517176)
1. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
Gelibter S; Orrico M; Filippi M; Moiola L
Mult Scler Relat Disord; 2021 Apr; 49():102775. PubMed ID: 33517176
[No Abstract] [Full Text] [Related]
2. Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets.
Moiola L; Riva A; Nicoletti F; Uccelli A; Salvetti M; Battistini L; Furlan R
Curr Neuropharmacol; 2022; 20(10):1811-1815. PubMed ID: 34923946
[TBL] [Abstract][Full Text] [Related]
3. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
[No Abstract] [Full Text] [Related]
5. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
[TBL] [Abstract][Full Text] [Related]
6. Normal antibody response after COVID-19 during treatment with cladribine.
Celius EG
Mult Scler Relat Disord; 2020 Nov; 46():102476. PubMed ID: 32882501
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
Buttari F; Bruno A; Dolcetti E; Azzolini F; Bellantonio P; Centonze D; Fantozzi R
Mult Scler Relat Disord; 2021 Jul; 52():102983. PubMed ID: 33990054
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.
Jack D; Damian D; Nolting A; Galazka A
Mult Scler Relat Disord; 2021 Jun; 51():102929. PubMed ID: 33813097
[TBL] [Abstract][Full Text] [Related]
9. Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets.
Jack D; Nolting A; Galazka A
Mult Scler Relat Disord; 2020 Nov; 46():102469. PubMed ID: 32919180
[No Abstract] [Full Text] [Related]
10. Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.
Mado H; Kubicka-Bączyk K; Adamczyk-Sowa M
J Int Med Res; 2021 Sep; 49(9):3000605211044378. PubMed ID: 34528472
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature.
Saraceno L; Susani EL; Marazzi MR; Moioli MC; Agostoni EC; Protti A
Neurol Sci; 2021 Dec; 42(12):4881-4884. PubMed ID: 34431013
[TBL] [Abstract][Full Text] [Related]
12. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients.
Mimpen M; Kreiter D; Kempkens T; Knippenberg S; Hupperts R; Gerlach O
Vaccine X; 2024 Jan; 16():100445. PubMed ID: 38304878
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Brownlee WJ
Mult Scler; 2020 Sep; 26(10):1267. PubMed ID: 32762499
[No Abstract] [Full Text] [Related]
15. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.
Albanese A; Sormani MP; Gattorno G; Schiavetti I
Mult Scler Relat Disord; 2022 Dec; 68():104156. PubMed ID: 36137347
[TBL] [Abstract][Full Text] [Related]
18. Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed.
Naser Moghadasi A
Mult Scler Relat Disord; 2021 Nov; 56():103263. PubMed ID: 34543859
[No Abstract] [Full Text] [Related]
19. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.
Bigaut K; Kremer L; Fabacher T; Lanotte L; Fleury MC; Collongues N; de Seze J
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34321333
[TBL] [Abstract][Full Text] [Related]
20. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
